The Lancet Summit: Preclinical Neurodegenerative Disease
27 - 29 January 2021 | QEII Centre, London
The biological paths that lead to Alzheimer’s disease and other neurodegenerative disorders start many years before clinical symptoms arise. In research settings, diagnostic criteria for these diseases now involve the use of biomarkers that reveal such pathophysiological changes.
Researchers are identifying and refining genetic, radiological, and CSF and blood biomarkers. At the same time, the effects on these biomarkers of therapies that could halt or delay neurodegeneration are being tested in clinical trials. These advances could ultimately enable Alzheimer’s disease and other neurodegenerative disorders to be prevented at preclinical stage.
Landmark biomarker and prevention studies, and hypothetical models of preclinical neurodegenerative diseaseshave been reported in The Lancet and The Lancet Neurology over the past decade. Reflecting our commitment to support this crucial area of neurological research, this Summit will provide a timely update on the latest advances and challenges in this area, with an emphasis on prevention.
The Summit will also provide a forum for discussion of the ethical and regulatory issues that these advances will bring about in research settings and clinical practice.
The programme will cover these topics:
- Genetics, cellular pathways, and neuronal vulnerability
- Biomarkers and early diagnosis
- Prevention through therapeutics
- Ethical and regulatory considerations
Elena Becker-Barroso, The Lancet Neurology Editor, UK
Nick Fox, University College London, UK
John Hardy, University College London, UK
Karen Duff, University College London, UK
Virginia Lee, University of Philadelphia, USA
Ammar Al-Chalabi, Kings College London, UK
Henrik Zetterberg, University College London, UK
David Klenerman, University of Cambridge, UK
Alexandra Durr, Institut National de la Santé et de la Recherche Médicale, Paris, France
Resia Sperling, Harvard Medical School, Boston, USA
Sarah Tabrizi, UCL Institute of Neurology, London, UK
Adam Boxer, UCSF Weill Institute for Neurosciences, San Francisco, USA
Timothy Miller, Washington University School of Medicine in St Louis, USA
Emmanuel Charpentier, Max Planck Unit for the Science of Pathogens, Berlin, Germany
Samantha Budd, Biogen, Boston, USA
Holly Kordasiewicz, Ionis Pharmaceuticals, San Diego, USA
Rachelle Doody, Roche, Geneva, Switzerland
Billy Dunn, US FDA, Washington, USA
Patricia Saidon, Sociedad Neurologica Argentina, Buenos Aires, Argentina
Eric Minikel, Broad Institute, Cambridge, USA
Michael Rawlins, Medicines and Healthcare Products Regulatory Agency, UK